MOXAVERINE HYDROCHLORIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C20H21NO2.ClH
Molecular Weight	343.847
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.CCC1=NC(CC2=CC=CC=C2)=C3C=C(OC)C(OC)=CC3=C1

InChI

InChIKey=DULZSDGCXSLVAQ-UHFFFAOYSA-N

InChI=1S/C20H21NO2.ClH/c1-4-16-11-15-12-19(22-2)20(23-3)13-17(15)18(21-16)10-14-8-6-5-7-9-14;/h5-9,11-13H,4,10H2,1-3H3;1H

HIDE SMILES / InChI

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C20H21NO2
Molecular Weight	307.3862
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23203292 | https://clinicaltrials.gov/ct2/show/NCT00709449

Moxaverine, a derivative of papaverine, is a phosphodiesterase inhibitor. Moxaverine has been studied in phase III of a clinical trial for the treatment of ocular blood flow in patients with age- related macular degeneration and primary open angle glaucoma. In addition, it has been studied in phase II of the clinical trial for the treatment of ischemia. This compound is prohibited by FEI (International Federation of equine).

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Phosphodiesterase 4 52 Target ID: CHEMBL2093863 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2854468	Inhibitor 8146

Conditions

Condition	Modality	Highest Phase	Product
Macular degeneration 4 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20456253	Primary	Phase III 651	Unknown Approved Use Unknown
Glaucoma 56 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20456253	Primary	Phase III 651	Unknown Approved Use Unknown
Ischemia 16 Sources: https://clinicaltrials.gov/ct2/show/NCT00569621	Primary	Phase II 1133	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Tissue distribution of moxaverine-hydrochloride in the rabbit eye and plasma.	2005 Jun	15969638
Effect of systemic moxaverine on ocular blood flow in humans.	2009 Nov	18778333

Patents

Sample Use Guides

In Vivo Use Guide

intravenous infusion of 150 mg in 250 ml NaCl, applied over 30 minutes.

Route of Administration: Intravenous

In Vitro Use Guide

Using a combination of techniques to assess quantitatively the shape and the filterability of red blood cells (RBC) after exposure to stress conditions (400 mosmol/l, lactacidosis, pH 6.8), the effects of 1-benzyl-3-ethyl-6,7-dimethoxy-isoquinoline hydrochloride (moxaverine-HCl, Kollateral) were tested. The shape of freely suspended RBC was quantified using the tangent count procedure. Moxaverine, when present in doses between 10(-5) und 10(-2) mol/l while the RBC are stressed, restored both the normal discoid red cell configuration and the microrheological performance when tested under low shear stresses. The data showed that moxaverine exerted protective effects on RBC membrane curvature and whole cell microrheological behavior (performance).

Substance Class	Chemical Created by `admin` on `Sat Dec 17 00:50:10 UTC 2022` Edited by `admin` on `Sat Dec 17 00:50:10 UTC 2022`
Record UNII	6R0I0E99CN
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

MOXAVERINE HYDROCHLORIDE

Common Name

English

1-BENZYL-6,7-DIMETHOXY-3-ETHYLISOQUINOLINE HYDROCHLORIDE

Systematic Name

English

MOXAVERINE HYDROCHLORIDE [MI]

Common Name

English

EUPAVERIN

Brand Name

English

Moxaverine hydrochloride [WHO-DD]

Common Name

English

PAVERINE HYDROCHLORIDE

Common Name

English

KOLLATERAL

Brand Name

English

EUPAVERINA

Brand Name

English

MOXAVERINE HCL

Common Name

English

Code System Code Type Description

ECHA (EC/EINECS)

214-607-5